Sign in Create account

Wockhardt Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: WOCKPHARMA BSE: 532300
₹2116.30
▼ -77.90 (-3.55%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
60/100
Moderate
Valuation
33/100
Fairly Valued
Momentum
50/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹34,388 Cr
PE (TTM)
96.6
Industry median 36.1 (152 companies)
Price to Book
6.5
PEG (TTM)
0.2
Institutions holding %
16.46%
FII + DII, latest filed period
Piotroski Score
6
Relative return vs Nifty50, qtr %
15.8
Relative return vs Sector, qtr %
7.8
Free Cash Flow
₹254 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
55.76%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
598.04%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
28.98%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
55.07%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
35.84%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.61
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.40
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
3.00
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
19.07%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
26.74%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
28.30%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
2.31%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
6.45%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
3.77%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 8 met
  • Yes Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 6)
  • Yes Debt to equity is below 0.5 (0.40)
  • No Return on equity is 15% or more (3.8%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (14.7% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.6%
Low 2106.2000 · High 2213.6000
1W return
-9.2%
Low 2106.2000 · High 2334.5000
1M return
12.3%
Low 1833.3000 · High 2360.0000
52W return
41.8%
Low 1086.7000 · High 2422.3000
Lifetime High ₹2329.7000 (Sept. 23, 2026)
Lifetime Low ₹68.2000 (March 12, 2009)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
2181.9
10D
2180.5
20D
2138.1
50D
2036.2
100D
1909.5
200D
1648.3

Delivery and volume

Day avg. delivery
34.9%
Week avg. delivery
37.3%
Month avg. delivery
34.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

2145.37
Pivot
First resistance2184.53
Second resistance2252.77
Third resistance2291.93
First support2077.13
Second support2037.97
Third support1969.73
Day RSI50.5
Day MFI54.6
Day MACD60.19
Day MACD signal66.83

Beta

1M2.46
3M1.23
1Y0.93
3Y1.23

Price change analysis

↑ 12.3%
Over 1 Month
LowHigh
1833.302360.00
↑ 7.8%
Over 3 Months
LowHigh
1792.402360.00
↑ 67.0%
Over 6 Months
LowHigh
1220.602422.30
↑ 41.8%
Over 1 Year
LowHigh
1086.702422.30
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 96.6 (own history: 60.2–575.2)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹561 Cr
Net profit (June 30, 2026)
₹107 Cr
Basic EPS (June 30, 2026)
₹6.6200

Ranks #21 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter49.08%
  • Mutual funds6.79%
  • FII/FPI7.22%
  • Other DII2.45%
  • Public34.46%

Largest holders

NameCategoryShares %Shares
Themisto Trustee Company Private LimitedPromoter40.1500%65244744
Pasithee Trustee Company Private LimitedPromoter2.7200%4420000
Ananke Trustee Company Private LimitedPromoter2.3500%3810693
Tata Mutual Fund - Tata Small Cap FundPublic2.0300%3301872
Callirhoe Trustee Company Private LimitedPromoter1.9200%3112079

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 49.08% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 7.09% to 7.22% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 8.12% to 6.79% in Jun 2026 qtr

22 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 205 insider trades, 38 SAST, 79 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
27 Dec 2024 Muayyad Khorakiwala Immediate relative Buy 0 ₹0
11 Mar 2022 Themisto Trustee Company Private Limited Promoter Pledge 0 ₹54.49 Cr
1 Mar 2022 Themisto Trustee Company Private Limited Promoter Pledge 0 ₹177.65 Cr
28 Dec 2021 Themisto Trustee Company Private Limited Promoter group Pledge 0 ₹74.85 Cr
2 Dec 2021 Themisto Trustee Company Private Limited Promoter group Pledge 0 ₹17.42 Cr
26 Oct 2021 Themisto Trustee Company Private Limited Promoter group Pledge 0 ₹62.41 Cr
11 Oct 2021 Themisto Trustee Company Private Limited Promoter group Pledge Revoke 0 ₹4.71 Cr
3 Sep 2021 Themisto Trustee Company Private Limited Promoter group Pledge 0 ₹49.98 Cr
3 Sep 2021 Themisto Trustee Company Private Limited Promoter group Pledge 0 ₹7.98 Cr
1 Sep 2021 Themisto Trustee Company Private Limited Promoter group Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 64 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
13 Nov 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 1,363,140 275.4900 NSE
13 Nov 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 1,363,140 275.6000 NSE
19 Jun 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 862,923 225.9100 NSE
19 Jun 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 859,924 225.8600 NSE
7 Dec 2022 KIRTAN MANEKLAL RUPARELIYA Bulk Sell 707 225.0000 BSE
7 Dec 2022 NEOMILE CORPORATE ADVISORY PRIVATE LIMITED Bulk Sell 2,600 225.0000 BSE
7 Dec 2022 KIRTAN MANEKLAL RUPARELIYA Bulk Buy 725,000 225.0000 BSE
7 Dec 2022 NEOMILE CORPORATE ADVISORY PRIVATE LIMITED Bulk Buy 1,532,498 225.0000 BSE
7 Dec 2022 HUMUZA CONSULTANTS Bulk Sell 2,500,000 225.0000 BSE
27 Aug 2021 KIRTAN MANEKLAL RUPARELIYA (HUF) Bulk Sell 783,340 402.7600 NSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
17 Nov 2016 Interim Dividend Rs 10/- Per Share (Purose Revised) 10.0000 19 Nov 2016
13 Nov 2014 Interim Dividend - Rs 20/- Per Share 20.0000 15 Nov 2014
17 Feb 2014 Interim Dividend - Rs 5/- Per Share 5.0000 19 Feb 2014
7 Nov 2013 Interim Dividend Rs.5/- Per Share 5.0000 8 Nov 2013
22 Aug 2013 Annual General Meeting / Dividend Rs.5 Per Share 5.0000 —
17 Apr 2008 Agm/Dividend-Rs2.50 Pr Sh 2.5000 —
22 Mar 2007 Interim Dividend-100% — 23 Mar 2007

Corporate Actions

Full history (26 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Wockhardt Ltd. to Wockhardt Life Sciences Ltd.
21 Jun 2024OTHERAnnual General Meeting
7 Aug 2023OTHERAnnual General Meeting
8 Mar 2022RIGHTSRights 3:10@ Premium Rs 220 Per Share
23 Jul 2021OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
10 Aug 2026 Financial Results Yes
4 May 2026 Financial Results/Fund Raising Yes
10 Feb 2026 Financial Results Yes
3 Nov 2025 Financial Results Yes
8 Aug 2025 Financial Results Yes

Corporate Announcements

All 886 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Trading Window Wockhardt Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Insider Trading / SAST Wockhardt Ltd - 532300 - Closure of Trading Window
25 Aug 2026 Action(s) taken or orders passed In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ( Listing Regulations ), we wish to inform you that the Company is in receipt of an Adjudication Order passed by the Commissioner of Customs, Nhava Sheva-II, JNCH.
25 Aug 2026 Copy of Newspaper Publication Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaper advertisement published today i.e 25th August, 2026, regarding the opening of special window for re-lodgement of the transfer requests of shares held in physical form.
10 Aug 2026 Shareholders meeting Disclosures relating to the 27th Annual General Meeting of Wockhardt Limited held on 10th August, 2026: A) Proceedings of the 27th AGM B) Scrutinizers Report on Voting Results of 27th AGM and C) Voting Results of 27th AGM.
10 Aug 2026 Monitoring Agency Report Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilization of proceeds of Qualified Institutions Placement ( QIP ) for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited, duly reviewed and taken on record by the Board of Directors & Audit Committee of the Company.
10 Aug 2026 Press Release Wockhardt Limited has informed the Exchange regarding a press release dated August 10, 2026, titled Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dialogue to Tackle Multidrug Resistance .
10 Aug 2026 Press Release Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026.
10 Aug 2026 Outcome of Board Meeting Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/027 dated 4th August, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 10th August, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026;
7 Aug 2026 Copy of Newspaper Publication Pursuant to Regulation 30 read with Schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of Newspaper extracts regarding the addendum to the Notice of 27th Annual General Meeting of the Company.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Healthy liquidity (Current Ratio 1.61)
  • Strong revenue growth YoY (35.8%)

Weaknesses

  • Low Return on Equity (3.8%)

Opportunities

  • PEG below 1 (0.15) -- earnings growth outpacing its own valuation

Threats

  • PE above 35 (96.6) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Single-stock futures available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.

Part of: NIFTY 500, NIFTY 500, NIFTY PHARMA, NIFTY PHARMA

Frequently asked questions about Wockhardt Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.